Editorial: Epigenetic and genetic mechanisms underlying cardiovascular diseases and neurodevelopmental disorders, volume II

Tada et al., 2021;Shi et al., 2022). Dissecting these etiological mechanisms is pivotal to advancing targeted therapeutic strategies for clinical management. This Research Topic presents ten articles including eight original research and two review articles, that collectively explore the genetics and epigenetic bases, as well as therapeutic targets, underlying these conditions. Epigenetic regulation, encompassing mechanisms such as DNA methylation, histone modification, and non-coding RNAs, serves as a critical intermediary, enabling environmental factors to influence gene expression without altering the DNA sequence itself, and plays a pivotal role in the onset and progression of CVD (Hartiala et al., 2021;Shi et al., 2022;Pang et al., 2024;Gao et al., 2026) Kawasaki disease (KD), an acute vasculitis primarily affecting young children, presents a significant challenge in pediatric healthcare. Nonetheless, the cellular heterogeneity and underlying pathogenic mechanisms of this disease remain inadequately understood (Vaňková et al., 2023;Burns, 2024). Their longitudinal study revealed phase-dependent changes in platelet parameters and identified the rs8090438 variant in the MBP gene as a potential genetic factor associated with reduced aspirin responsiveness.Pulmonary arterial hypertension and chronic heart failure present substantial challenges within the domain of CVD (Chizinga et al., 2018;Heidenreich et al., 2022;Wu et al., 2025;Liu et al., 2026). In this Research Topic, one original Abnormalities in the genetic architecture of CVD have been extensivelydocumented; however, their genetic etiologies remain largely elusive (Heimlich et al., 2022;Yu et al., 2023;Qiao et al., 2025). Addressing this critical knowledge gap, two